Sol-gel technologies and galderma announce exclusive licenses for the commercialization of epsolay® and twyneo® in the united states

Ness ziona, israel & lausanne, switzerland--(business wire)--sol-gel technologies, ltd. (nasdaq: slgl), a clinical-stage dermatology company, and galderma, the world's largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of epsolay® and twyneo® in the united states. under these agreements, galderma has an exclusive license to commercialize sol-gel's most advanced investigational drug products using sol-gel's
SLGL Ratings Summary
SLGL Quant Ranking